At ISPOR EU in Barcelona in November 2024, we showcased over 30 posters, delivered three engaging panels, and conducted a short course on advanced survival modeling techniques. Explore some of our posters from the conference and gain valuable insights.
Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. Together we can unlock possibilities. For information about OPEN Health’s services and how we could support you, please get in touch. Contact us
- Stakeholder Engagement in HTA: A Matter for Consensus?
- Predicting acceptability of quantitative evidence synthesis for joint clinical assessment submissions: A rating scale
- Patients’ Consensus on PICO Scoping for Health Technology Assessment (HTA) Under the New EU Regulation: Preliminary Findings Using a Modified Delphi Methodology
- Self-sustainability in HTA: Is a proportionate approach really proportionate?
- Who Will Be Shaping European Health Technology Assessment (HTA)? A Scoring System to Anticipate Individual Countries’ Influence on, and Uptake of, Joint Clinical Assessments (JCA) in the European Union (EU)
- Utilizing generative artificial intelligence in network meta-analysis: Assessing the effectiveness of GenAI as a tool in feasibility assessments
- Heterogeneity in Biomarker Data Collection, Recording and Availability across European Sources of Oncology RWD & Potential Impacts on Pan-EU HTA Assessment
- Identifying and Appraising Real-World Evidence Data Sources for the Overweight and Obesity Population Across the EU4 and the United Kingdom
- Literature Review on the Use of Synthetic Data and AI Advances for Patient-Centered, Sustainable HEOR
- From Data to Decisions: Decision-Makers’ Perceptions of Artificial Intelligence-Powered Evidence Synthesis in HTA Submissions
- Are the machines ready to take over? Can artificial intelligence replace a human reviewer for literature screening and selection for systematic literature reviews?
- Comparative Efficacy of Treatments in Advanced/Metastatic Pancreatic Cancer: Demonstrating the Power of Multilevel Network Meta-Regression
- Early Value Assessments (EVAs) for MedTech by NICE. What can we learn so far?
- Incorporating Social Determinants of Health (SDOH) Into a Screening Tool Using Machine Learning to Predict Lung Cancer Diagnosis
- Feasibility of Target Trial Emulation (TTE) study design using the Hospital Episode Statistics (HES) database in England
- Indirect Treatment Comparisons: Current Practice and the Added Value of Multi-Level Network Meta-Regression
Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. Together we can unlock possibilities. For information about OPEN Health’s services and how we could support you, please get in touch. Contact us
